永利3044(中国集团)有限公司官网

分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

NPC2 suppresses osteolytic metastasis in lung adenocarcinoma via the AKT/mTOR pathway and tumor-osteoclast crosstalk

Si Zhou, Ning Li, Ruping Li, Ying Ding, Yichen Zhu, Yan Pan, Yan Liu, Yingying Zhang, Hui Yang, Qiming Wang

Journal:iScience

IF:4.1

DOI:10.1016/j.isci.2026.115017

PMID:41816293

Published:2026-02-13

research field:肿瘤学分子生物学细胞信号传导骨骼生物学癌症转移

Abstract

The lysosomal-related protein NPC2 affects the occurrence and development of tumors in terms of stemness, gene mutational burden, and microsatellite instability of tumor cells. Here, combining with our previous scRNA-seq data, we identified the protective role of NPC2 in bone metastasis of lung adenocarcinoma (LUAD). Bone metastases exhibited lower NPC2 expression compared to primary tumors, and low NPC2 expression was associated with poorer LUAD patient survival. NPC2 knockdown LUAD cells exhibited enhanced migration capability, and their supernatant accelerated the osteoclast differentiation and maturation. In vivo , NPC2 knockdown promoted the development of osteolytic lesions induced by PC9 cells, whereas NPC2 overexpression partially rescued these lesions. We also found that these effects might be mediated via the AKT/mTOR signaling pathway and crosstalk between cancer cells and osteoclasts. These findings indicate that NPC2 plays a critical role in the osteolytic metastasis of LUAD and may represent a promising therapeutic target for this disease. Biological sciences; Cancer

本文使用的Yeasen产品

购物车
客服
转染试用
XML 地图